China Resources Shuanghe announced that Beijing Shuanghe Runchuang Technology Co., Ltd., a wholly-owned subsidiary of the company, received a notice from the US FDA to conduct clinical trials of DC7001A capsules in the US. The drug is intended to be used to treat systemic lupus erythematosus. The drug has previously been approved for clinical trials by the State Drug Administration. As of the announcement date, the company had invested a total of 17.9897 million yuan in research and development of the drug. Currently, the drug is in the early stages of clinical development. Subsequent clinical studies need to be completed and approved before it can be marketed. There is uncertainty about development and marketing.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.